Eli Lilly to Offer Higher Doses of Zepbound Directly to Consumers Online

Direct-to-Consumer Zepbound Sales

• 🚀 Eli Lilly announced that starting in early August, cash-paying customers can order the two highest doses of its weight-loss drug Zepbound directly from the company's website.
• 💰 This initiative offers doses up to 15 milligrams for $499 per month or less, regardless of insurance status.

Expanding Access and Competition

• 💡 The LillyDirect website, launched last year, aims to expand patient access to certain drugs and compete with compounded or cheaper versions.
• 📉 In February, Lilly reduced Zepbound prices and expanded dose options for cash-paying customers on its website.
• 🏥 CVS Health decided to drop Zepbound from some reimbursement lists starting July 1st, while continuing to cover Novo Nordisk's drug after price negotiations.

Market Landscape and Leadership

• 📈 Both Eli Lilly and Novo Nordisk are competing in the significant obesity drug market, estimated at $150 billion.
• 🥇 Recent prescription data suggests Eli Lilly has taken the lead in this market, surpassing Novo Nordisk despite their earlier entry.